Aluvia 200/50 FC Tablets

Aluvia 200/50 FC Tablets

S4

API: Lopinavir, Ritonavir | Company: AbbVie

Clinical Summary

Quick overview from the medicine insert

Indication

Treatment of HIV-1 infection in combination with other antiretroviral agents.

Dosage (summary)

The recommended dose is 400 mg Lopinavir/100 mg Ritonavir (2 tablets) taken orally twice daily with food.

Onset of Action / Duration

Viral load reduction may be observed within 2 weeks, but optimal response may take several months.

Special Populations

  • Hepatic impairment
  • Renal impairment
  • Elderly patients
  • Pediatric patients

Pregnancy & Breastfeeding

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Ritonavir is excreted in breast milk; breastfeeding is not recommended.

Key Drug Interactions

  • CYP3A4 inhibitors and inducers
  • Anticonvulsants (e.g., phenytoin, carbamazepine)
  • Antituberculosis agents (e.g., rifampicin)
  • St. John's Wort
  • Certain antidepressants (e.g., trazodone)

Contraindications

  • Hypersensitivity to Lopinavir, Ritonavir, or any component of the formulation
  • Severe hepatic impairment
  • Concomitant use with certain medications that are contraindicated due to significant drug interactions

Common side effects

  • Diarrhea
  • Nausea
  • Vomiting
  • Abdominal pain
  • Fatigue
  • Headache
  • Hyperlipidemia

Counselling Points

  • Take with food to enhance absorption.
  • Adhere strictly to the prescribed regimen.
  • Report any signs of liver dysfunction (e.g., jaundice, dark urine).
  • Inform healthcare provider of all medications being taken.
  • Discuss potential side effects and when to seek medical attention.

Serious warnings

  • Risk of developing resistance if not taken as prescribed.
  • Monitor for signs of pancreatitis.
  • Potential for metabolic changes including hyperglycemia and lipid abnormalities.
  • Caution in patients with a history of cardiovascular disease.
Important Disclaimer

The Aluvia 200/50 FC Tablets professional information leaflet below is the property of AbbVie and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>

Healthcare Professionals Only

This content is for registered healthcare professionals

Sign in or create a free account to read the full package insert.

Free for HPCSA-registered professionals. Powered by Medinsert.

Successfully Stashed! 💊

This package insert has been safely stored in your digital medical cabinet. No prescription needed to view it later!

View My Favourites